NCT04145232View on ClinicalTrials.gov

AImmune - Artificial Intelligence Algorithm for Identification of Immunogenic Neoepitopes of Cancer to Predict and Boost Patient's Response to Immunotherapies.

UnknownOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

June 13, 2019

Primary Completion Date

October 15, 2020

Study Completion Date

November 30, 2020

Conditions
Non Small Cell Lung CancerNeoepitopesNeoantigensImmunotherapyNext Generation Sequencing (NGS)Personalized Neoantigen Cancer Vaccine
Interventions
BIOLOGICAL

Collection of biopsy (FFPE), blood (PBMC) and stool

Patients receiving routine treatment (immunotherapy using anti-PD1 / anti-PDL1 and / or anti CTLA4 antibodies), financed by the Polish National Health Fund (NFZ).

Trial Locations (1)

Unknown

RECRUITING

University Clinical Centre in Gdansk, Gdansk

Sponsors

Lead Sponsor

Ardigen
All Listed Sponsors
collaborator

Małopolskie Centre of Entrepreneurship

UNKNOWN

lead

Ardigen

INDUSTRY

NCT04145232 - AImmune - Artificial Intelligence Algorithm for Identification of Immunogenic Neoepitopes of Cancer to Predict and Boost Patient's Response to Immunotherapies. | Biotech Hunter | Biotech Hunter